Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14076200 | 0.86 | ALDH1A1 (0.53) | SLC6A3KMT2AOPRM1ALDH1A1MAPT | |
| SCHEMBL14046309 | 0.80 | SLC6A3 (0.59) | SLC6A3KMT2AOPRM1ALDH1A1MAPT | |
| SCHEMBL14046295 | 0.80 | SLC6A3 (0.59) | SLC6A3KMT2AOPRM1ALDH1A1MAPT | |
| SCHEMBL14046323 | 0.77 | SLC6A3 (0.63) | SLC6A3KMT2AOPRM1ALDH1A1MAPT | |
| SCHEMBL14046310 | 0.77 | SLC6A3 (0.56) | SLC6A3KMT2AOPRM1ALDH1A1MAPT | |
| SCHEMBL10855621 | 0.71 | KMT2A (0.55) | SLC6A3KMT2AOPRM1ALDH1A1MAPT | |
| SCHEMBL10654646 | 0.71 | KMT2A (0.55) | SLC6A3KMT2AOPRM1ALDH1A1MAPT | |
| Flazalone SCHEMBL43716 | 0.71 | KMT2A (1.00) | SLC6A3KMT2AOPRM1ALDH1A1MAPT | |
| SCHEMBL10654641 | 0.71 | KMT2A (0.55) | SLC6A3KMT2AOPRM1ALDH1A1MAPT | |
| SCHEMBL6041735 | 0.70 | KMT2A (0.57) | SLC6A3KMT2AOPRM1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234280-A1 | Use of Mc4 Receptor Agonist Compounds | MCMURRAY GORDON | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234280-A1 | Use of Mc4 Receptor Agonist Compounds | MC4R, MC5R, GPR4 | SLC6A3 773/4885KMT2A 3266/4885OPRM1 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.